{'fraction_non_alphanumeric': 0.03537170263788969, 'fraction_numerical': 0.01618705035971223, 'mean_word_length': 4.897526501766785, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EFFICACY OF AEROBIC VERSUS RESISTANCE TRAINING ON DYSPNEA AND CRP LEVELS IN POST-COVID-19 PATIENTS

: Objective: to compare the effect of aerobic versus resistance training on Dyspnea and CRP levels in post-COVID-19 patients. Participants and methods : Sixty young adults volunteer patients of both sex (26 men & 34 women) with Past history of COVID-19 after recovery since 2 to 4 months, their age ranged from 18 to 35 years, their body mass index (BMI) ranged from 18.5 to 35 Kg/m2, they were selected and referred from the Outpatient clinic and the Emergency department of Al-Mataria Teaching Hospital, Cairo, Egypt. They were subdivided into two groups equal in numbers; group A received an aerobic exercise (AE) program in form of cycle ergometer protocols for six weeks and group B received upper and lower body resistance training (RT) using free weights for six weeks, and evaluated through measuring Modified Borg Scale to measure Breathlessness (dyspnea score) & blood levels of C- reactive protein (CRP). Results: It revealed that a statistical significant decrease (P<0.05) in Modified Borg scale and CRP levels within each group. Comparison between groups (A) and (B) at the end of the study showed that, there was a statistically significant decrease in Borg scale in favor to group (A). On the other side, there wasn’t statistically significant difference between them in CRP levels. Conclusion: According to the findings of this study, both aerobic exercise and resistance training interventions are effective in improving CRP levels and Modified Borg scale score. But, aerobic training is more effective in improving dyspnea in post COVID-19 patients.